Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis: Interim data from OPAL Balance, an open label, long-term extension study

Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2017
This article has no abstract
Epistemonikos ID: 963e02b45199b818e12ce98a9264d4e7d6686138
First added on: Feb 08, 2025